Drug · CHEMBL44
GENISTEIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. GENISTEIN. Drugs and targets, record CHEMBL44. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL44
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
(-)-.alpha.-isosparteine, .alpha.-isospartein, .alpha.-isosparteine, .alpha.-isosparteine, (-)-, .alpha.-sparteine, 11-isosparteine, 4',5,7-trihydroxyisoflavone, BIO 300, BIO-300, FW-635I-2, Genisteina, Genisteine, Genisteine-alkaloid, Isosparteine, alpha-, NPI-031L, NSC-36586, NSC-366737, SIPI-807-1, Sophoricol, Sparteine l-.alpha.-isosparteine
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases30
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 30Source Open Targets
See all 30 diseasesTrials35
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 7 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00290758 | Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer | Phase 2 | 126 | 2017-02-08 | genistein | Its name | ClinicalTrials.gov |
| NCT00287690 | Isoflavones and the Coronary Circulation in Men and Women With Coronary Artery Disease | Phase 2/3 | 71 | 2019-08-05 | genistein | Its name | ClinicalTrials.gov |
| NCT00118040 | Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer | Phase 2 | 60 | 2016-03-24 | genistein | Its name | ClinicalTrials.gov |
| NCT01489813 | Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment | Phase 2 | 36 | 2024-07-25 | genistein | Its name | ClinicalTrials.gov |
| NCT04650555 | BIO 300 Oral Powder Safety and Pharmacokinetics | Phase 1 | 34 | 2024-05-03 | genistein | Its name | ClinicalTrials.gov |
| NCT02567799 | BIO 300 Non-Small Cell Lung Cancer Study | Phase 1/2 | 21 | 2023-12-20 | genistein | Its name | ClinicalTrials.gov |
| NCT00376948 | Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Phase 2 | 20 | 2014-08-26 | genistein | Its name | ClinicalTrials.gov |
| NCT00244933 | Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer | Phase 2 | 19 | 2015-02-02 | genistein | Its name | ClinicalTrials.gov |
| NCT01325311 | Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer | Phase 2 | 15 | 2016-08-03 | genistein | Its name | ClinicalTrials.gov |
| NCT01985763 | Genistein in Treatment of Metastatic Colorectal Cancer | Phase 1/2 | 13 | 2019-05-10 | genistein | Its name | ClinicalTrials.gov |
1 to 10 of 35
See all 35 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm A (Genistein) vs Arm B (Placebo): serious adverse events | 6 of 62 | 1 of 64 | 126 | NCT00290758 | Trial comparisons |
| Sugar Pill vs Genistein Supplement: deaths from any cause | 0 of 16 | 0 of 20 | 36 | NCT01489813 | Trial comparisons |
| Sugar Pill vs Genistein Supplement: serious adverse events | 0 of 16 | 0 of 20 | 36 | NCT01489813 | Trial comparisons |
| Sugar Pill vs Genistein Supplement: Number of Participants With Cancer Recurrence Determined at 10-week Biopsy. | 7 of 14 | 10 of 18 | 32 | NCT01489813 | Trial comparisons |
| Genistein vs Genistein and Chemotherapy: deaths from any cause | 0 of 13 | 0 of 13 | 26 | NCT01985763 | Trial comparisons |
| Genistein vs Genistein and Chemotherapy: serious adverse events | 0 of 13 | 0 of 13 | 26 | NCT01985763 | Trial comparisons |
| Genistein vs Placebo: deaths from any cause | 0 of 13 | 0 of 12 | 25 | NCT00287690 | Trial comparisons |
| Genistein vs Placebo: serious adverse events | 0 of 13 | 0 of 12 | 25 | NCT00287690 | Trial comparisons |
| Arm I (Cholecalciferol, Genistein) vs Arm II (Placebo): serious adverse events | 0 of 7 | 0 of 8 | 15 | NCT01325311 | Trial comparisons |
| Genistein vs Placebo: deaths from any cause | 0 of 6 | 0 of 4 | 10 | NCT02766478 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials10
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL44
GET https://conductscience.org/api/drugs/v1/CHEMBL44/diseases?page=2